Compare AbCellera Biologics Inc (ABCL) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Vanguard S&P 500 ETF — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Vanguard S&P 500 ETF trades at $683.84. Which is the better fit depends on your goals.
| ABCL | VOO | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $8.12 | $698.29 |
52-Week Low | $2.78 | $570.23 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
VOO, the Vanguard S&P 500 ETF, trades at $690.58, up 0.87% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF tracks the S&P 500, offering broad exposure to large-cap U.S. equities. Recent news highlights sector rotation and AI-driven market volatility, with strategists projecting further index gains. A dividend of $1.96 is scheduled for late June 2026.
The outlook for VOO remains positive given its diversification and the S&P 500's earnings momentum, though risks include tech sector concentration and potential market corrections. Long-term investors may find value in its low-cost, passive approach to U.S. equity exposure despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
